AstraZeneca

Fortress Biotech achieved a 20.5% increase in net revenue to $17.6 million in Q3 2025, driven by strong performance from its dermatology products portfolio.

Oxford-based Scripta Therapeutics emerged from stealth with a $12M seed round to pioneer a biology-first approach to drug discovery targeting transcription factors.

The Centers for Medicare & Medicaid Services announced the GENEROUS Model, a voluntary pilot program launching in 2026 that will allow participating state Medicaid programs to purchase select drugs at prices aligned with those paid in other developed countries.

Axsome Therapeutics has acquired exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of Baergic Bio from Avenue Therapeutics.

AstraZeneca exercised its option to acquire obesity startup SixPeaks Bio for $170 million upfront, with an additional $30 million in two years and up to $100 million in regulatory milestone payments.

Neok Bio launched with $75 million in Series A funding to develop bispecific antibody-drug conjugates that simultaneously target two distinct cancer proteins.

BioInvent will present early Phase 2a data at ASH 2025 showing that the triple combination of BI-1206, rituximab, and acalabrutinib is safe and well-tolerated in relapsed/refractory NHL patients.

The FDA announced new draft guidance to simplify biosimilar approval by reducing clinical testing requirements and shortening development timelines.

Alembic Pharmaceuticals Limited received final FDA approval for its generic ticagrelor tablets 60mg, therapeutically equivalent to AstraZeneca's Brilinta.

AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.